Korro Bio Statistics
Total Valuation
Korro Bio has a market cap or net worth of $186.81 million. The enterprise value is $103.51 million.
| Market Cap | 186.81M |
| Enterprise Value | 103.51M |
Important Dates
The last earnings date was Thursday, November 5, 2026, before market open.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Korro Bio has 13.73 million shares outstanding. The number of shares has increased by 50.71% in one year.
| Current Share Class | 13.73M |
| Shares Outstanding | 13.73M |
| Shares Change (YoY) | +50.71% |
| Shares Change (QoQ) | +1.41% |
| Owned by Insiders (%) | 0.86% |
| Owned by Institutions (%) | 72.00% |
| Float | 8.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 144.59 |
| Forward PS | 92.77 |
| PB Ratio | 2.11 |
| P/TBV Ratio | 2.11 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 80.11 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.30, with a Debt / Equity ratio of 0.47.
| Current Ratio | 7.30 |
| Quick Ratio | 7.04 |
| Debt / Equity | 0.47 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -87.90 |
Financial Efficiency
Return on equity (ROE) is -113.26% and return on invested capital (ROIC) is -34.78%.
| Return on Equity (ROE) | -113.26% |
| Return on Assets (ROA) | -30.73% |
| Return on Invested Capital (ROIC) | -34.78% |
| Return on Capital Employed (ROCE) | -57.15% |
| Weighted Average Cost of Capital (WACC) | 13.08% |
| Revenue Per Employee | $22,276 |
| Profits Per Employee | -$1.83M |
| Employee Count | 58 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Korro Bio has paid $1.10 million in taxes.
| Income Tax | 1.10M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -56.68% in the last 52 weeks. The beta is 2.07, so Korro Bio's price volatility has been higher than the market average.
| Beta (5Y) | 2.07 |
| 52-Week Price Change | -56.68% |
| 50-Day Moving Average | 11.86 |
| 200-Day Moving Average | 12.17 |
| Relative Strength Index (RSI) | 52.39 |
| Average Volume (20 Days) | 227,981 |
Short Selling Information
The latest short interest is 1.75 million, so 12.74% of the outstanding shares have been sold short.
| Short Interest | 1.75M |
| Short Previous Month | 1.73M |
| Short % of Shares Out | 12.74% |
| Short % of Float | 20.40% |
| Short Ratio (days to cover) | 8.93 |
Income Statement
In the last 12 months, Korro Bio had revenue of $1.29 million and -$106.13 million in losses. Loss per share was -$7.50.
| Revenue | 1.29M |
| Gross Profit | -41.01M |
| Operating Income | -76.12M |
| Pretax Income | -105.03M |
| Net Income | -106.13M |
| EBITDA | -74.37M |
| EBIT | -76.12M |
| Loss Per Share | -$7.50 |
Balance Sheet
The company has $124.82 million in cash and investments and $41.52 million in debt, with a net cash position of $83.30 million or $6.07 per share.
| Cash & Investments | 124.82M |
| Total Debt | 41.52M |
| Net Cash | 83.30M |
| Net Cash Per Share | $6.07 |
| Equity (Book Value) | 88.37M |
| Book Value Per Share | 6.44 |
| Working Capital | 94.01M |
Cash Flow
In the last 12 months, operating cash flow was -$63.71 million and capital expenditures -$169,000, giving a free cash flow of -$63.87 million.
| Operating Cash Flow | -63.71M |
| Capital Expenditures | -169,000 |
| Depreciation & Amortization | 1.75M |
| Net Borrowing | n/a |
| Free Cash Flow | -63.87M |
| FCF Per Share | -$4.65 |
Margins
| Gross Margin | n/a |
| Operating Margin | -5,891.49% |
| Pretax Margin | -8,129.41% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Korro Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -50.71% |
| Shareholder Yield | -50.71% |
| Earnings Yield | -55.14% |
| FCF Yield | -34.19% |
Analyst Forecast
The average price target for Korro Bio is $21.50, which is 57.97% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $21.50 |
| Price Target Difference | 57.97% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Korro Bio has an Altman Z-Score of -3.33 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.33 |
| Piotroski F-Score | 2 |